January 2023
New KDIGO Executive Committee Members Begin Their Term
KDIGO has elected five new members to its Executive Committee. They began their three-year term on January 1, 2023. The KDIGO Executive Committee is the foundation’s governing body, which sets its policies and priorities and is made up of twenty kidney disease experts from around the world. A Nominating Committee elects members of the Executive Committee following a formal process of seeking suggestions from the global kidney community. The 2023 Executive Committee will maintain its composition of members from each continent and an equal balance between women and men.
New members for 2023 are:
  • Sunita Bavanandan (Malaysia)
  • Michelle Denberg (United States)
  • Michelle O’Shaughnessy (Ireland)
  • Patrick Rossignol (Monaco)
  • Rita Suri (Canada)
Retiring members are:
  • Mustafa Arici (Turkey)
  • Tara Chang (United States)
  • Fan Fan Hou (China)
  • Jolanta Malyszko (Poland)
  • Laura Sola (Uruguay)
The KDIGO Executive Committee is co-chaired by Michel Jadoul, MD (Belgium), Wolfgang Winkelmayer, MD, MPH, ScD (United States), and Co-Chair Elect, Morgan Grams, MD, PhD, MHS (United States).
“The KDIGO Executive Committee is thrilled to welcome these outstanding clinicians, and we are fortunate to have them,” said Dr. Jadoul. “They bring a wealth of expertise and insights to the mission and management of KDIGO and will lead the organization well into the future.”
KDIGO sincerely thanks our retiring Executive Committee Members for the countless hours of volunteer service they have given to our community and to our patients,” said Dr. Winkelmayer. “We look forward to opportunities to reengage with them on future KDIGO projects and activities.”
New Episodes of the KDIGO Conversations in Nephrology Podcast
Have you listened to the KDIGO Conversations in Nephrology podcast? The podcast features global experts covering a wide range of topics related to kidney disease. The latest three-episode series, hosted by Marlies Ostermann, MD (United Kingdom), focuses on acute kidney injury (AKI).


Dr. Ostermann and Dr. Javier Neyra (United States) explore the role of kidney replacement therapy in managing fluid overload. In episode eight, The Role of Hemodynamics for AKI and Maintaining Hemodynamic Stability in KRT Patients, Dr. Ostermann and Dr. Rinaldo Bellomo (Australia) discuss the importance of hemodynamic stabilization in protecting kidney function for patients on kidney replacement therapy. In episode nine, Best Practices in Nutrition, Drug Management, and Multi-Organ Support in Patients with AKI, Dr. Ostermann and Dr. Sandra Kane-Gill (United States) discuss the importance of drug stewardship when treating critically ill patients.
You can access the podcasts on most major podcast platforms via AnchorFM or on the KDIGO Podcasts webpage.
New Resources

KDIGO-PlatformQ Health Webinar: Physiologic Regulation of EPO Production for CKD-Anemia: An Opportunity to Enhance Access to Care

In this on-demand KDIGO-PlatformQ program, a panel of expert nephrologists and patient advocates explore the current treatment landscape for anemia in CKD, including iron supplementation and the use of erythropoiesis-stimulating agents. Panelists review emerging agents and investigational hypoxia-inducible factor prolyl hydroxylase inhibitors, including their mechanism of action, efficacy, and safety. The program also addresses strategies to improve access to anemia care for under-resourced and diverse patient populations. Register for the program.

KDIGO-PlatformQ Health Webinar: New Directions about IgAN Treatment and Why it Matters to Me

KDIGO: New Directions about IgAN Treatment and Why it Matters to Me is an hour-long presentation that consists of four easy-to-understand modules on the guideline-driven management of IgAN and finding the best treatment for each patient. The program features a panel of expert clinicians, a patient advocate, and a patient.

Module 1, “Why Is the KDIGO Guideline Important to Patients with IgAN?”, covers the KDIGO Guidelines, how they were written, and the levels of recommendation within. Module 2, “Understanding IgAN,” addresses key terms associated with IgAN for patients, how IgAN is diagnosed, and the importance of controlling aspects of the disease process. Module 3, “What Does KDIGO Say About IgAN Treatment?”, explores the goals of treatment, options to slow the disease and the flow of protein in urine, and how patients can take an active role in management. Finally, Module 4, “What’s New and What’s Next to Reduce Proteinuria?”, addresses new and emerging agents for IgAN, lifestyle changes to improve kidney health, and treatment opportunities offered by clinical trials. Register for the program.
Beyond ACEis and ARBs: The Promise of SGLT2 Inhibition to Reduce Risk of Kidney Failure and Dialysis in Numerous Patient Populations

Check out the KDIGO-PlatformQ Health free CME program, Beyond ACEis and ARBs: The Promise of SGLT2 Inhibition to Reduce Risk of Kidney Failure and Dialysis in Numerous Patient Populations. The program is chaired by Meg Jardine, MD (Australia), and features Ramy Hanna, MD (United States) and Silvio Inzucchi, MD (United States). Register for the program.
Russian Translations: The KDIGO 2021 Glomerular Diseases Guideline and Key Takeaways


The KDIGO 2021 Glomerular Diseases Guideline and Key Takeaways are now available in Russian. ed by the Russian Dialysis Society (RDS), edited by E.V. Zakharova, and translated by I.N. Bobkova, N.M. Bulanov, E.V. Zakharova, A.Y. Zemchenkov, E.S. Kamyshova, E.V. Parshina, L.S. Prikhodina, A.D. Putintseva, A.N. Shvedova; edited by E.V. Zakharova.


Visit the KDIGO Glomerular Diseases Guideline page for more resources.
KDIGO is a Belgian foundation committed to developing and implementing nephrology guidelines that improve patient outcomes on a global basis. KDIGO is independent, volunteer-led, self-managed, and accountable to the public and the patients it serves. Learn More.


Back to News